Risk Factors for Tigecycline-Associated Hypofibrinogenemia

Jia Liu,1 Yingying Yan,2 Fan Zhang1 1Department of Geriatrics, Peking University Third Hospital, Beijing, People’s Republic of China; 2Department of Pharmacy, Peking University Third Hospital, Beijing, People’s Republic of ChinaCorrespondence: Fan ZhangDepartment of Geriatrics, P...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Liu J, Yan Y, Zhang F
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	tigecycline hypofibrinogenemia coagulation disorders risk factors Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/29de2747630c4bdd91dee82307a72f01
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:29de2747630c4bdd91dee82307a72f01
record_format	dspace
spelling	oai:doaj.org-article:29de2747630c4bdd91dee82307a72f012021-12-02T18:03:16ZRisk Factors for Tigecycline-Associated Hypofibrinogenemia1178-203Xhttps://doaj.org/article/29de2747630c4bdd91dee82307a72f012021-04-01T00:00:00Zhttps://www.dovepress.com/risk-factors-for-tigecycline-associated-hypofibrinogenemia-peer-reviewed-article-TCRMhttps://doaj.org/toc/1178-203XJia Liu,1 Yingying Yan,2 Fan Zhang1 1Department of Geriatrics, Peking University Third Hospital, Beijing, People’s Republic of China; 2Department of Pharmacy, Peking University Third Hospital, Beijing, People’s Republic of ChinaCorrespondence: Fan ZhangDepartment of Geriatrics, Peking University Third Hospital, 49 North Garden Road, Beijing, 100191, People’s Republic of ChinaTel +86-010-82265685Email zhangfan_puh3@yeah.netBackground: With the widespread use of tigecycline, especially in elderly people infected with multidrug-resistant bacteria, the associated coagulation disorders are attracting the attention of clinicians. The risk factors of tigecycline-associated hypofibrinogenemia are still controversial.Purpose: The aims of our study were to explore the related factors of hypofibrinogenemia caused by tigecycline, and to establish the risk assessment criteria for tigecycline-associated hypofibrinogenemia.Patients and Methods: This was an observational retrospective cohort study of patients treated for at least 3 days with tigecycline. Hypofibrinogenemia was defined as plasma fibrinogen < 2.0 g/L. Risk factors were determined using logistic regression analysis, and the risk assessment criteria were identified by using receiver operating characteristic curves.Results: In total, 148 patients were included in the analysis, mean age was 77.09± 15.11 years old. Ninety patients who developed hypofibrinogenemia during tigecycline treatment with mean plasma fibrinogen of 1.42 g/L were included in the hypofibrinogenemia group, the other 58 patients with mean plasma fibrinogen of 2.68 g/L were included in the normal group. In the multivariate analysis, age (p = 0.035), tigecycline treatment duration (p = 0.044), and baseline fibrinogen level (p = 0.002) were independently associated with hypofibrinogenemia. An age of ≥ 82 years, ≥ 9 days of medication, and a baseline fibrinogen level of ≤ 3.5 g/L were selected for predicting hypofibrinogenemia. Hypofibrinogenemia was independently associated with bleeding (OR 8.96, 95% CI [1.132– 70.946], p = 0.038).Conclusion: Hypofibrinogenemia is a common adverse effect of tigecycline in our study. Elderly patients are more prone to developing hypofibrinogenemia after the administration of tigecycline. It is independently associated with bleeding but not death. The risk assessment criteria can help in the identification of patients with high risk of hypofibrinogenemia.Keywords: tigecycline, hypofibrinogenemia, coagulation disorders, risk factorsLiu JYan YZhang FDove Medical Pressarticletigecyclinehypofibrinogenemiacoagulation disordersrisk factorsTherapeutics. PharmacologyRM1-950ENTherapeutics and Clinical Risk Management, Vol Volume 17, Pp 325-332 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	tigecycline hypofibrinogenemia coagulation disorders risk factors Therapeutics. Pharmacology RM1-950
spellingShingle	tigecycline hypofibrinogenemia coagulation disorders risk factors Therapeutics. Pharmacology RM1-950 Liu J Yan Y Zhang F Risk Factors for Tigecycline-Associated Hypofibrinogenemia
description	Jia Liu,1 Yingying Yan,2 Fan Zhang1 1Department of Geriatrics, Peking University Third Hospital, Beijing, People’s Republic of China; 2Department of Pharmacy, Peking University Third Hospital, Beijing, People’s Republic of ChinaCorrespondence: Fan ZhangDepartment of Geriatrics, Peking University Third Hospital, 49 North Garden Road, Beijing, 100191, People’s Republic of ChinaTel +86-010-82265685Email zhangfan_puh3@yeah.netBackground: With the widespread use of tigecycline, especially in elderly people infected with multidrug-resistant bacteria, the associated coagulation disorders are attracting the attention of clinicians. The risk factors of tigecycline-associated hypofibrinogenemia are still controversial.Purpose: The aims of our study were to explore the related factors of hypofibrinogenemia caused by tigecycline, and to establish the risk assessment criteria for tigecycline-associated hypofibrinogenemia.Patients and Methods: This was an observational retrospective cohort study of patients treated for at least 3 days with tigecycline. Hypofibrinogenemia was defined as plasma fibrinogen < 2.0 g/L. Risk factors were determined using logistic regression analysis, and the risk assessment criteria were identified by using receiver operating characteristic curves.Results: In total, 148 patients were included in the analysis, mean age was 77.09± 15.11 years old. Ninety patients who developed hypofibrinogenemia during tigecycline treatment with mean plasma fibrinogen of 1.42 g/L were included in the hypofibrinogenemia group, the other 58 patients with mean plasma fibrinogen of 2.68 g/L were included in the normal group. In the multivariate analysis, age (p = 0.035), tigecycline treatment duration (p = 0.044), and baseline fibrinogen level (p = 0.002) were independently associated with hypofibrinogenemia. An age of ≥ 82 years, ≥ 9 days of medication, and a baseline fibrinogen level of ≤ 3.5 g/L were selected for predicting hypofibrinogenemia. Hypofibrinogenemia was independently associated with bleeding (OR 8.96, 95% CI [1.132– 70.946], p = 0.038).Conclusion: Hypofibrinogenemia is a common adverse effect of tigecycline in our study. Elderly patients are more prone to developing hypofibrinogenemia after the administration of tigecycline. It is independently associated with bleeding but not death. The risk assessment criteria can help in the identification of patients with high risk of hypofibrinogenemia.Keywords: tigecycline, hypofibrinogenemia, coagulation disorders, risk factors
format	article
author	Liu J Yan Y Zhang F
author_facet	Liu J Yan Y Zhang F
author_sort	Liu J
title	Risk Factors for Tigecycline-Associated Hypofibrinogenemia
title_short	Risk Factors for Tigecycline-Associated Hypofibrinogenemia
title_full	Risk Factors for Tigecycline-Associated Hypofibrinogenemia
title_fullStr	Risk Factors for Tigecycline-Associated Hypofibrinogenemia
title_full_unstemmed	Risk Factors for Tigecycline-Associated Hypofibrinogenemia
title_sort	risk factors for tigecycline-associated hypofibrinogenemia
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/29de2747630c4bdd91dee82307a72f01
work_keys_str_mv	AT liuj riskfactorsfortigecyclineassociatedhypofibrinogenemia AT yany riskfactorsfortigecyclineassociatedhypofibrinogenemia AT zhangf riskfactorsfortigecyclineassociatedhypofibrinogenemia
_version_	1718378740698841088

Risk Factors for Tigecycline-Associated Hypofibrinogenemia

Ejemplares similares